Accutane (isotretinoin) remains the most effective acne treatment available, though it’s also a subject of considerable discussion. While some media coverage has focused on less substantiated side effects, the risk of birth defects is a definitive concern, making Accutane unsuitable for women who may become pregnant.
To minimize Accutane-related birth defects, the FDA has implemented strict guidelines. The iPLEDGE program, a national registry, requires all individuals taking Accutane (or its generic forms) and those who prescribe or dispense it to enroll. This mandatory enrollment aims to closely monitor and control the drug’s distribution and use.
Under iPLEDGE, every patient, regardless of gender, must register in the iPLEDGE system. Prescribing physicians also need to register to continue prescribing isotretinoin. Pharmacies and drug wholesalers must register to receive shipments of the medication.
For women, the program includes additional safeguards. They must undergo two pregnancy tests, conducted in a laboratory or doctor’s office, before receiving their initial prescription and then a monthly pregnancy test before each refill. Home pregnancy tests are not accepted. Doctors are required to enter the pregnancy test results into the iPLEDGE system, and women must obtain their prescription within a seven-day window.
Furthermore, women must commit to using two forms of contraception while taking Accutane. They must also self-register on iPLEDGE to confirm their adherence to this requirement. While self-reporting has limitations, the FDA views it as an additional measure to reinforce the medication’s risks.
Pharmacists play a crucial role by verifying patient compliance with iPLEDGE requirements in the database before dispensing any prescription.
The FDA estimates that approximately 100,000 Accutane and generic isotretinoin prescriptions are filled monthly. Since Accutane’s introduction in 1982, the FDA has received reports of over 2,000 pregnancies among users, with potentially more unreported cases. While most pregnancies resulted in abortion or miscarriage, over 160 infants were born with Accutane-related birth defects. The iPLEDGE program seeks to significantly reduce these numbers through stringent monitoring and control.